Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma? 2011

L Moureau-Zabotto, and F Viret, and M Giovaninni, and B Lelong, and E Bories, and J R Delpero, and C Pesenti, and F Caillol, and C de Chaisemartin, and M Minsat, and G Monges, and A Sarran, and M Resbeut
Radiation Oncology Department, Institut Paoli Calmettes, Marseille, France. moureaul@marseille.fnclcc.fr

BACKGROUND This study retrospectively describes the outcome of a series of 38 patients (pts) with T4 anal carcinoma exclusively treated by radio and chemotherapy. METHODS From 1992 to 2007, 38 pts with UST4-N0-2-M0 anal carcinoma were treated with exclusive radiotherapy and chemotherapy. All patients received external beam radiotherapy (EBRT) (median dose 45 Gy) with a concomitant chemotherapy (5-fluorouracil-cisplatin). Eleven patients received neo-adjuvant chemotherapy (5-fluorouracil-cisplatin). After 2-8 weeks, a 15-20 Gy boost was delivered either with EBRT (20 pts) or interstitial (192)Ir brachytherapy (18 pts). Mean follow-up was 66 months. RESULTS After chemoradiation therapy (CRT), 13 pts (34%) had a complete response, 23 pts (60%) a response >50% (2 pts were not evaluated). The 5-year-disease-free survival was 79.2 ± 6.5%, and the 5-year overall survival was 83.9 ± 6%. Eight patients developed tumor progression (mean delay 8.8 months), six of them requiring a salvage surgery with definitive colostomy for local relapse. Late severe complication requiring colostomy was observed in 2 pts. The 5-year-colostomy-free survival was 78 ± 6.9%. Patients who received primary chemotherapy had a statistically significant better 5-year colostomy-free survival (100% vs. 38 ± 16.4%, P = 0.0006). CONCLUSIONS T4 anal carcinoma can be treated with a curative intent using a sphincter-sparing approach of CRT, and neo-adjuvant chemotherapy should be considered prior to radiotherapy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D001918 Brachytherapy A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues. Curietherapy,Implant Radiotherapy,Plaque Therapy, Radioisotope,Radioisotope Brachytherapy,Radiotherapy, Interstitial,Radiotherapy, Intracavity,Radiotherapy, Surface,Brachytherapy, Radioisotope,Interstitial Radiotherapy,Intracavity Radiotherapy,Radioisotope Plaque Therapy,Radiotherapy, Implant,Surface Radiotherapy,Therapy, Radioisotope Plaque
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

L Moureau-Zabotto, and F Viret, and M Giovaninni, and B Lelong, and E Bories, and J R Delpero, and C Pesenti, and F Caillol, and C de Chaisemartin, and M Minsat, and G Monges, and A Sarran, and M Resbeut
January 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
L Moureau-Zabotto, and F Viret, and M Giovaninni, and B Lelong, and E Bories, and J R Delpero, and C Pesenti, and F Caillol, and C de Chaisemartin, and M Minsat, and G Monges, and A Sarran, and M Resbeut
October 2010, Gynecologic oncology,
L Moureau-Zabotto, and F Viret, and M Giovaninni, and B Lelong, and E Bories, and J R Delpero, and C Pesenti, and F Caillol, and C de Chaisemartin, and M Minsat, and G Monges, and A Sarran, and M Resbeut
January 1998, Tumori,
L Moureau-Zabotto, and F Viret, and M Giovaninni, and B Lelong, and E Bories, and J R Delpero, and C Pesenti, and F Caillol, and C de Chaisemartin, and M Minsat, and G Monges, and A Sarran, and M Resbeut
June 2002, European journal of nuclear medicine and molecular imaging,
L Moureau-Zabotto, and F Viret, and M Giovaninni, and B Lelong, and E Bories, and J R Delpero, and C Pesenti, and F Caillol, and C de Chaisemartin, and M Minsat, and G Monges, and A Sarran, and M Resbeut
August 2003, American journal of surgery,
L Moureau-Zabotto, and F Viret, and M Giovaninni, and B Lelong, and E Bories, and J R Delpero, and C Pesenti, and F Caillol, and C de Chaisemartin, and M Minsat, and G Monges, and A Sarran, and M Resbeut
June 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
L Moureau-Zabotto, and F Viret, and M Giovaninni, and B Lelong, and E Bories, and J R Delpero, and C Pesenti, and F Caillol, and C de Chaisemartin, and M Minsat, and G Monges, and A Sarran, and M Resbeut
January 2014, International journal of surgery (London, England),
L Moureau-Zabotto, and F Viret, and M Giovaninni, and B Lelong, and E Bories, and J R Delpero, and C Pesenti, and F Caillol, and C de Chaisemartin, and M Minsat, and G Monges, and A Sarran, and M Resbeut
May 1986, Wiener klinische Wochenschrift,
L Moureau-Zabotto, and F Viret, and M Giovaninni, and B Lelong, and E Bories, and J R Delpero, and C Pesenti, and F Caillol, and C de Chaisemartin, and M Minsat, and G Monges, and A Sarran, and M Resbeut
February 2000, International journal of colorectal disease,
L Moureau-Zabotto, and F Viret, and M Giovaninni, and B Lelong, and E Bories, and J R Delpero, and C Pesenti, and F Caillol, and C de Chaisemartin, and M Minsat, and G Monges, and A Sarran, and M Resbeut
December 2008, Nature clinical practice. Oncology,
Copied contents to your clipboard!